Showing results (71-80 of 233) with videos related to

Sort By:
Pageof 24
Cancer Research|November 4, 2005
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myelomaRamesh B Batchu, Amberly M Moreno, Susann M Szmania, et al.
British Journal of Haematology|July 13, 2010
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patientsQing Yi, Susann Szmania, John Freeman, et al.
Blood|May 27, 2010
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee, Jackie Szymonifka, Elias Anaissie, et al.
Blood|June 12, 2009
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocolsAntje Hoering, John Crowley, John D Shaughnessy, et al.
Blood|January 12, 2013
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3Saad Z Usmani, Alan Mitchell, Sarah Waheed, et al.
Cancers|September 28, 2023
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease ProgressionWen Ling, Sarah K Johnson, Syed J Mehdi, et al.
Clinical Lymphoma|July 3, 2003
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survivalMaurizio Zangari, Bart Barlogie, Raymond Thertulien, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Leukemia Research|July 27, 2023
Growth and dormancy control of myeloma cells by mesenchymal stem cellsSyed J Mehdi, Kalyan Ghatak, Wen Ling, et al.
Blood|December 21, 2011
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaJeffrey A Zonder, Ann F Mohrbacher, Seema Singhal, et al.
Pageof 24